Our website is having a makeover! www.thecasecentre.org will be unavailable from 10h (BST) on Saturday 31 July until 17h on Sunday 1 August while our team makes the new site live.

Product details

Share this page:
Please find below the full details of the product you clicked a link to view.
Published by:
Amity Research Centers (2016)
10 pages
Data source:
Published sources
This item is part of a free case collection. For terms & conditions go to www.thecasecentre.org/freecaseterms


The age-old problems of drug counterfeiting had long been faced by the government authorities and the pharma industries alike. It had been a problem of global scale with some countries and regions showing more vulnerability. There had been a range of factors causing the problem of drug counterfeiting that included inadequate regulatory measures, perceived profitability, difficulties associated with their accurate detection and so on. With time the trade became a formidable challenge to the global community, so much so, it came to be termed as 'The crime of the 21st century'. Countries like India largely faced the menace of counterfeit drugs owing to its very socio-ecological dynamics, sometimes even putting the country's hard earned reputation in the pharma sector at stake. While the problems were increasingly becoming acute, there had been measures initiated by both the government and the corporate fraternity to counter them in an emphatic way. But every measure was having a challenge or two entangling it. Inconclusiveness of a drug to be declared as counterfeit was one of the major challenges alongside regulatory bottlenecks. Still, some positive endeavours had been underway in the relentless strife against the illicit trade of counterfeiting drugs. Now it remained to be seen to what extent countries like India would succeed in combating the challenges of drug counterfeiting, which had manifold economic implications among others. This case is part of the Amity Research Centers free case collection (visit www.thecasecentre.org/amityfreecases for more information on the collection).


Tax revenues; Economic consequences; Repackaging and relabelling; Drug counterfeiting; SSFFC medical products
Other setting(s):
2010 - 2016

Access this item

View our pricing guide
or to see prices.

Reviews & usage